Regeneration Biomedical, Inc. (RBI) announced positive interim results from its Phase 1 clinical trial of a novel Alzheimer’s diseaseAlzheimer’s disease (AD) therapy. The therapy, involving direct brain injections of Wnt-activated, autologous, expanded, adipose-derived stem cells (RB-ADSCs), has shown promising safety and efficacy data in five patients. The data, which will be presented at the International Society for Cell & Gene Therapy (ISCT) annual meeting, also earned the abstract a Host Region (US West) Award.

These findings are particularly noteworthy given the urgent need for new AD treatments. Current therapies mainly target amyloid plaques, often with significant side effects. RBI’s approach addresses multiple aspects of AD, including inflammation and stem cell regeneration, potentially offering a more holistic and safer alternative. The early positive signals on cognitive improvement, coupled with a favorable safety profile, suggest a potential breakthrough in treating this debilitating disease.

The interim data, covering a follow-up period of 23 to 55 weeks post-single injection, showed improvement in several key areas. Eighty percent of patients demonstrated improvements in ADAS-Cog scores and normalized p-Tau and amyloid beta levels, while 60% showed improvements in MMSE scores. Importantly, no major adverse events were reported. The trial, which uses a 3+3 single-dose escalation design, is ongoing and will ultimately enroll nine patients with mild-to-moderate AD to determine the recommended dose for a Phase 2 trial.

This early success suggests a potential paradigm shift in AD treatment. If these positive trends continue in larger trials, RB-ADSC therapy could offer a much-needed, novel therapeutic option for AD patients. This could also pave the way for exploring its application in other neurodegenerative diseases, signifying significant progress in regenerative medicine and potentially revolutionizing the treatment landscape for these conditions.

Source link: https://www.globenewswire.com/news-release/2025/05/05/3073944/0/en/Regeneration-Biomedical-to-Present-Updated-Phase-1-Trial-Data-on-Autologous-Stem-Cell-Therapy-Injected-Directly-into-the-Brain-for-Alzheimer-s-Disease-in-Podium-Presentation-at-the.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.